Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo C, Tadayoni R, Talks J, Wolf S.

Retina. 2015 Jun 12. [Epub ahead of print]

PMID:
26076215
2.

Defining response to anti-VEGF therapies in neovascular AMD.

Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly S, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y.

Eye (Lond). 2015 Jun;29(6):721-731. doi: 10.1038/eye.2015.48. Epub 2015 Apr 17. Review.

PMID:
25882328
3.

Wide-field imaging and OCT vs clinical evaluation of patients referred from diabetic retinopathy screening.

Manjunath V, Papastavrou V, Steel DH, Menon G, Taylor R, Peto T, Talks J.

Eye (Lond). 2015 Mar;29(3):416-23. doi: 10.1038/eye.2014.320. Epub 2015 Jan 16.

4.

Two week, OCT-based follow-up as guidance for retreatment with ranibizumab for CNV apparently refractory to therapy.

Manousaridis K, Talks J.

Eur J Ophthalmol. 2015 May-Jun;25(3):235-40. doi: 10.5301/ejo.5000545. Epub 2014 Nov 29.

PMID:
25449645
5.

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

Chakravarthy U, Williams M; AMD Guidelines Group.

Eye (Lond). 2013 Dec;27(12):1429-31. doi: 10.1038/eye.2013.233. Epub 2013 Oct 25. No abstract available. Erratum in: Eye (Lond). 2013 Dec;27(12):1432. multiple investigator names added.

6.

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC; IVAN study investigators.

Lancet. 2013 Oct 12;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19.

7.

Information used to decide on retreatment of exudative age-related macular degeneration with 
anti-VEGF in clinical practice.

Manousaridis K, Manjunath V, Talks J.

Eur J Ophthalmol. 2012 Aug 6:0. doi: 10.5301/ejo.5000190. [Epub ahead of print]

PMID:
22890600
8.

Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

Manousaridis K, Talks J.

Br J Ophthalmol. 2012 Feb;96(2):179-84. doi: 10.1136/bjophthalmol-2011-301087. Review.

PMID:
22250209
9.

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.

Loftus JV, Sultan MB, Pleil AM; Macugen 1013 Study Group.

Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7498-505. doi: 10.1167/iovs.11-7613.

PMID:
21896838
10.

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.

Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study Group.

Ophthalmology. 2011 Jun;118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045. Epub 2011 May 6.

PMID:
21529957
11.

Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes.

Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, Grieve R, Patton WP, Muldrew KA, Peto T, Chakravarthy U; Verteporfin Photodynamic Therapy Cohort Study Group.

Ophthalmology. 2009 Dec;116(12):e1-8. doi: 10.1016/j.ophtha.2009.10.022.

PMID:
19948275
12.

Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment.

Amoaku W; National Institute for Health and Clinical Excellence; Royal College of Ophthalmologists (RCOphth); Department of Health.

Eye (Lond). 2009 Nov;23(11):2140-2. doi: 10.1038/eye.2008.241. Epub 2008 Aug 1. No abstract available.

PMID:
18670458
13.
14.

Measuring visual acuity in general practice. Helps decide on urgency.

Talks J, Lindenbaum K, Hopkisson B.

BMJ. 1995 Mar 11;310(6980):671. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk